Ironwood Pharma Reports Top-Line Phase IIa Data From IW-1973: 'Addition of IW-1973 to ongoing medical regimens used to treat diabetic patients with hypertension showed reductions in blood pressure, fasting plasma glucose, cholesterol and triglycerides...'